SG11201811230RA - Compositions and methods for reducing ocular neovascularization - Google Patents

Compositions and methods for reducing ocular neovascularization

Info

Publication number
SG11201811230RA
SG11201811230RA SG11201811230RA SG11201811230RA SG11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA SG 11201811230R A SG11201811230R A SG 11201811230RA
Authority
SG
Singapore
Prior art keywords
international
suite
pct
methods
menlo park
Prior art date
Application number
SG11201811230RA
Inventor
Mark Blumenkranz
Mehdi Gasmi
Original Assignee
Adverum Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc
Publication of SG11201811230RA publication Critical patent/SG11201811230RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1111111111 0111011110111110101111111 011111111101111111111111110111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/218981 A2 21 December 2017 (21.12.2017) WIP0 I PCT (51) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) (71) (72) Inventors: BLUMENKRANZ, Mark; (74) International Patent Classification: (81) Designated States A61K 48/00 (2006.01) Cl 2N 15/861 (2006.01) PCT/US2017/038012 16 June 2017 (16.06.2017) English English Priority Data: 62/351,231 16 June 2016 (16.06.2016) US (84) Designated States Applicant: ADVERUM BIOTECHNOLOGIES, INC. [US/US]; 1035 O'Brien Drive, Suite A, Menlo Park, CA 94025 (US). 1035 O'Brien Dri- ye, Suite A, Menlo Park, CA 94025 (US). GASMI, Mehdi; 1035 O'Brien Drive, Suite A, Menlo Park, CA 94025 (US). Agent: YIN, Eva F. et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US). (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — = = Title: COMPOSITIONS AND METHODS FOR REDUCING OCULAR NEOVASCULARIZATION : The present disclosure provides pharmaceutical compositions and methods thereof neovascularization, such as having a nucleic acid sequence that encodes an anti-VEGF agent. (54) FIG. 1 for the prevention or treatment of composition comprising a rAAV = \ \• \ \,, , k , ,,. ,, ' , •,„N•k \ , % ‘ • ' = = = = - = = ei 11 GC C:r GC 11 ei IN ,-1 (57) 0 ocular ei vector AMD, in a subject, by administering to the subject a pharmaceutical [Continued on next page] WO 2017/218981 A2 MIMMOMMIONMEMIHMOIMMOIIIMEHMIE Published: — without international search report and to upon receipt of that report (Rule 48.2(g)) be republished
SG11201811230RA 2016-06-16 2017-06-16 Compositions and methods for reducing ocular neovascularization SG11201811230RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351231P 2016-06-16 2016-06-16
PCT/US2017/038012 WO2017218981A2 (en) 2016-06-16 2017-06-16 Compositions and methods for reducing ocular neovascularization

Publications (1)

Publication Number Publication Date
SG11201811230RA true SG11201811230RA (en) 2019-01-30

Family

ID=60664289

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811230RA SG11201811230RA (en) 2016-06-16 2017-06-16 Compositions and methods for reducing ocular neovascularization

Country Status (17)

Country Link
US (2) US20190100582A1 (en)
EP (2) EP4083203A1 (en)
JP (3) JP6990667B2 (en)
KR (2) KR102622823B1 (en)
AU (2) AU2017286680B2 (en)
CA (1) CA3027740A1 (en)
DK (1) DK3472317T3 (en)
ES (1) ES2916344T3 (en)
HR (1) HRP20220612T1 (en)
HU (1) HUE059424T2 (en)
LT (1) LT3472317T (en)
PL (1) PL3472317T3 (en)
PT (1) PT3472317T (en)
RS (1) RS63282B1 (en)
SG (1) SG11201811230RA (en)
SI (1) SI3472317T1 (en)
WO (1) WO2017218981A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000741B2 (en) 2014-03-17 2018-06-19 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7095994B2 (en) 2015-03-02 2022-07-05 アドヴェラム バイオテクノロジーズ， インコーポレイテッド Compositions and Methods for Intravitreal Delivery of Polynucleotides to the Retinal Pyramids
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP7343903B2 (en) 2017-03-17 2023-09-13 アドヴェラム バイオテクノロジーズ， インコーポレイテッド Compositions and methods for enhancing gene expression
KR20200090927A (en) 2017-12-19 2020-07-29 아카우오스, 인크. AAV-mediated delivery of therapeutic antibodies to the inner ear
CN111989397A (en) * 2018-03-30 2020-11-24 藤堂具纪 Oncolytic virus with inhibited swelling development
WO2021050094A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
JP2022552262A (en) * 2019-10-07 2022-12-15 リジェネックスバイオ インコーポレイテッド Adeno-associated virus vector pharmaceutical compositions and methods
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021163451A1 (en) * 2020-02-14 2021-08-19 Asklepios Biopharmaceutical, Inc. Method of treating gene therapy associated toxicity with antibiotics
CN115869425A (en) * 2022-12-12 2023-03-31 北京生物制品研究所有限责任公司 AAV ophthalmic injection and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0694042T3 (en) 1993-03-25 2005-02-14 Merck & Co Inc Vascular endothelial cell growth factor inhibitor
WO2010040772A2 (en) * 2008-10-07 2010-04-15 Bracco Research Sa Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
SG10202110919YA (en) * 2011-04-22 2021-11-29 Univ California Adeno-associated virus virions with variant capsid and methods of use thereof
TWI775096B (en) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
US10000741B2 (en) * 2014-03-17 2018-06-19 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
EP3570895A1 (en) * 2017-01-17 2019-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors

Also Published As

Publication number Publication date
EP3472317A4 (en) 2020-02-26
EP3472317A2 (en) 2019-04-24
AU2017286680B2 (en) 2023-01-19
AU2023202277A1 (en) 2023-05-11
CA3027740A1 (en) 2017-12-21
US20230322911A1 (en) 2023-10-12
DK3472317T3 (en) 2022-05-23
JP7384447B2 (en) 2023-11-21
EP3472317B1 (en) 2022-03-16
SI3472317T1 (en) 2022-08-31
WO2017218981A3 (en) 2018-02-15
ES2916344T3 (en) 2022-06-30
JP6990667B2 (en) 2022-02-03
LT3472317T (en) 2022-06-27
PL3472317T3 (en) 2022-08-08
RS63282B1 (en) 2022-06-30
KR20220162881A (en) 2022-12-08
KR20190038536A (en) 2019-04-08
JP2019521989A (en) 2019-08-08
EP4083203A1 (en) 2022-11-02
HUE059424T2 (en) 2022-11-28
JP2022028928A (en) 2022-02-16
AU2017286680A1 (en) 2019-01-31
US20190100582A1 (en) 2019-04-04
JP2023171953A (en) 2023-12-05
WO2017218981A2 (en) 2017-12-21
HRP20220612T1 (en) 2022-07-22
PT3472317T (en) 2022-06-27
KR102622823B1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811432WA (en) Rna for cancer therapy
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201909011PA (en) Niraparib compositions
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201805001UA (en) Method of treating influenza a
SG11201900238UA (en) Compounds and methods for modulation of smn2